Current Role of Dacomitinib in Head and Neck Cancer.

Details

Serval ID
serval:BIB_252EC8A01882
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Current Role of Dacomitinib in Head and Neck Cancer.
Journal
Expert opinion on investigational drugs
Author(s)
Elicin O., Ozsahin M.
ISSN
1744-7658 (Electronic)
ISSN-L
1354-3784
Publication state
Published
Issued date
06/2016
Peer-reviewed
Oui
Volume
25
Number
6
Pages
735-742
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Abstract
Recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) has a dismal prognosis. With the emergence of monoclonal antibodies and tyrosine kinase inhibitors (TKI) targeting the epidermal growth factor receptor (EGFR), several drugs were developed and tested in HNSCC. To date, the monoclonal antibody cetuximab is the only approved therapy for curative and recurrent/metastatic patients. Other EGFR-targeting drugs either failed in the clinical trials or are still in the early phases of drug development and research.
In this article, previously published data and ongoing studies regarding dacomitinib, a second-generation irreversible TKI, for the treatment of HNSCC are presented and discussed.
The current body of evidence is not mature enough to indicate the use of dacomitinib for the treatment of HNSCC in curative or in recurrent/metastatic settings. Phase II data suggest the potential of improved outcome in selected recurrent/metastatic HNSCC based on several biomarkers, which need to be evaluated in randomized phase III trials. Meanwhile, an ongoing phase I study is investigating dacomitinib's optimal dosing combined with and without cisplatin in the curative concomitant chemoradiotherapy setting.

Keywords
Animals, Antineoplastic Agents/pharmacology, Antineoplastic Agents/therapeutic use, Carcinoma, Squamous Cell/drug therapy, Carcinoma, Squamous Cell/pathology, Head and Neck Neoplasms/drug therapy, Head and Neck Neoplasms/pathology, Humans, Neoplasm Metastasis, Neoplasm Recurrence, Local, Prognosis, Protein Kinase Inhibitors/pharmacology, Protein Kinase Inhibitors/therapeutic use, Quinazolinones/pharmacology, Quinazolinones/therapeutic use, Receptor, Epidermal Growth Factor/antagonists & inhibitors
Pubmed
Create date
19/04/2016 17:12
Last modification date
20/08/2019 13:03
Usage data